Potential bias associated with modeling the effectiveness of treatment using an overall hazard ratio

Alarid-Escudero, Fernando
2014-10

View/Download File

DisSpec_HR_poster.pdf (326.87 KB)

Persistent link to this item

http://hdl.handle.net/11299/193364
Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

Potential bias associated with modeling the effectiveness of treatment using an overall hazard ratio

Authors

Published Date

2014-10

Publisher

SAGE

Type

Other

Abstract

Purpose: Clinical trials often report treatment efficacy in terms of the reduction of all-cause mortality [i.e., overall hazard ratio (OHR)], and not the reduction in disease-specific mortality [i.e., disease-specific hazard ratio (DSHR)]. Using an OHR to reduce all-cause mortality beyond the time horizon of the clinical trial may introduce bias if the relative proportion of other-cause mortality increases with age. We aim to quantify this bias. Methods: We simulated a hypothetical cohort of patients with a generic disease that increases the age-, sex-, and race-specific mortality rate (μASR) by a constant additive disease-specific rate (μDis). We assumed a DSHR of 0.75 (unreported) and an OHR of 0.80 (reported, derived from DSHR and assumptions of clinical trial population). We quantified the bias in terms of the difference in life expectancy (LE) gains with treatment between using an OHR approach to reduce all-cause mortality over a lifetime [(μASR+ μDis)xOHR] compared with using a DSHR approach to reduce disease-specific mortality [μASR+(μDis)xDSHR]. We varied the starting age of the cohort from 40 to 70 years old. Results: The OHR bias increases as DSHR decreases and with younger starting ages of the cohort. For a cohort of 60 year-old sick patients, the mortality rate under OHR approach crosses μASR at the age of 90 (see figure) and LE gain is overestimated by 0.6 years (a 3.7% increase). We also used OHR as an estimate of DSHR [μASR+(μDis)xOHR] (as the latter is not often reported). This resulted in a slight shift in the mortality rate compared to the DSHR approach (see figure), yielding in an underestimation of the LE gain. Conclusions: The use of an OHR approach to model treatment effectiveness beyond the time horizon of the trial overestimates the effectiveness of the treatment. Under an OHR approach it is possible that sick individuals at some point will face a lower mortality rate compared with healthy individuals. We recommend either to derive a DSHR from trials and use the DSHR approach, or to use the OHR as an estimate of DSHR in the model, which is a conservative assumption.

Keywords

Description

Poster presented at the 36th Annual Meeting of the Society for Medical Decision Making in Miami, FL, October 2014

Related to

Replaces

License

Collections

School of Public Health Graduate Research

Series/Report Number

Medical Decision Making;

Funding information

Isbn identifier

Doi identifier

Previously Published Citation

Suggested citation

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.